SAN DIEGO, April  28, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Erasca, Inc. (NASDAQ:ERAS). The investigation focuses on Erasca&#39;s executive officers and

ERAS

Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Erasca Faces Legal Investigation Over Securities Violations

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, April  28, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Erasca, Inc. (NASDAQ:ERAS). The investigation focuses on Erasca&amp;#39;s executive officers and</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Erasca, Inc. is currently facing scrutiny under federal securities laws following allegations of misleading clinical trial data comparisons. This has resulted in a significant stock price drop, leading to potential liability for the company and creating actionable opportunities for investors to assess future direction.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Erasca is under investigation for potential securities law violations.</li><li>Allegations claim improper comparisons of clinical trial data.</li><li>Erasca denies the claims and plans to contest them vigorously.</li><li>Company&#039;s stock price decreased significantly post-disclosure.</li><li>Investors may join the investigation if they incurred losses.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Revolution Medicines, Inc. (RVMD)</strong>: Allegations from this company are influencing ERAS&#039;s legal scrutiny.</li><li><strong>Erasca, Inc. (ERAS)</strong>: Facing major legal and investor sentiment challenges post-disclosure.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under Corporate Developments, focusing on legal implications that affect share valuation and investor confidence, crucial in biotech sectors where data integrity is paramount.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Erasca&#039;s stock has already faced a substantial decline after recent disclosures.</li><li>Ongoing investigations could create further uncertainty in stock performance.</li><li>Positive or negative outcomes from the investigation may significantly sway investor sentiment.</li><li>Continued negative press could hinder potential partnerships or collaborations.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Erasca reported a stock price decline following the legal allegations.</li><li>The allegations involve comparisons between ERAS-0015 and RMC-6236.</li><li>Erasca plans to contest allegations presented by Revolution Medicines, Inc.</li><li>Johnson Fistel is leading the investigation into Erasca&#039;s disclosures.</li><li>Investors can join the investigation if they suffered losses on Erasca securities.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>ERAS might experience continued volatility in the short term due to these legal concerns.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, April  28, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ERAS">ERAS</a>). The investigation focuses on Erasca's executive officers and whether investor losses may be recovered under federal securities laws.</p>  <p><strong>What if I purchased Erasca securities?</strong><br></br>If you purchased Erasca securities and suffered losses on your investment, join our investigation now: <a href="https://www.globenewswire.com/Tracker?data=dwD7Dh17FvKzp9oObP3zxl-kq9KcOz4qYGWT69v_nT-JEgGalK-8xcySQSsgHHs-PREdhaLp4LLV9sdbpD9ytLRUkZ18Z1Ap3mC2-ajpcHJpOr3aDzd_bF5aeZ9js9MM0YQzwkrsYCD4-iUDBSki12Zet8ZDHzXaUK2_p836VNw=" rel="nofollow" target="_blank">Click here to join the investigation</a>.<br></br>Or for more information, contact Jim Baker at <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> or (619) 814-4471.<br></br>There is no cost or obligation to you.</p>  <p><strong>Background of the investigation</strong><br></br>On April 27, 2026, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for Revolution Medicines, Inc. alleging, among other things, that Erasca had "improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures" and demanding that the Company cease making "deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236." Erasca stated that it believes the assertions are without merit and intends to contest the allegations vigorously.</p>  <p>Erasca also reported preliminary Phase 1 clinical data for ERAS-0015 in a separate Form 8-K filing. Among other things, the Company reported response-rate data that included both confirmed and unconfirmed responses across patient cohorts of varying sizes. The Company further stated that comparisons between ERAS-0015 and other product candidates, including RMC-6236, were based on cross-study analyses and "not based on any head-to-head clinical trials," and cautioned that such comparisons are "inherently limited" and "may not be directly comparable."</p>  <p>Following these disclosures, Erasca's stock price declined significantly, damaging investors.</p>  <p>In light of this disclosure, Johnson Fistel is investigating whether Erasca complied with the federal securities laws. If you suffered losses from your investment in Erasca stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=j4ItIG0TDYaxVlPugDL6xk0XaOriUE7-OkvdjKXLEejbOFQC5IEwWJIO_cAb75c1eOW0wpWcVmnG0JepIuVKCYSbUvHsfhUd67gG9RnH72g=" rel="nofollow" target="_blank">www.johnsonfistel.com</a>.</p>  <p><strong>Achievements</strong><br></br>In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm's effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.</p>  <p>Attorney advertising.<br></br>Past results do not guarantee future outcomes.<br></br>Services may be performed by attorneys in any of our offices.<br></br>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471 &#x7C; <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> &#x7C; <a href="mailto:fjohnson@johnsonfistel.com">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcwODU3MSM3NTcwMTMwIzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NTRiOTBjYmYtZDQ4ZC00MDVlLThjYjYtYmVkMWYzMzZmZDQwLTExOTMzNTgtMjAyNi0wNC0yOC1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Erasca, Inc. is currently facing scrutiny under federal securities laws following allegations of misleading clinical trial data comparisons. This has resulted in a significant stock price drop, leading to potential liability for the company and creating actionable opportunities for investors to assess future direction.

Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News